Carter Denise P. 4
4 · Quoin Pharmaceuticals, Ltd. · Filed Sep 5, 2024
Insider Transaction Report
Form 4
Carter Denise P.
DirectorChief Operating Officer
Transactions
- Purchase
Ordinary Shares
2024-09-03$0.63/sh+1,822$1,139→ 11,179 total - Purchase
Ordinary Shares
2024-09-03$0.66/sh+4,100$2,686→ 15,279 total - Purchase
Ordinary Shares
2024-09-04$0.75/sh+8,825$6,602→ 24,104 total - Purchase
Ordinary Shares
2024-09-04$0.80/sh+22,988$18,310→ 47,092 total
Footnotes (2)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.
- [F2]Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023.